抗苗勒管激素在多囊卵巢综合征发病及诊治中的作用.

Polycystic ovary syndrome (PCOS) is a relatively common female reproductive endocrine and metabolic disorder with complex etiology and pathogenesis. Recent studies have found that anti-Müllerian hormone (AMH) is an important factor affecting the pathophysiology of PCOS. AMH is closely related to follicular development, hyperandrogenism, hypothalamic -pituitary -ovarian axis and heredity. AMH can inhibit primordial follicle recruitment and small sinus follicle growth, and prevent premature ovarian failure. AMH also exacerbates follicular growth and development disorders by interacting with androgens. In addition, AMH can activate the discharge of gonadotropin-releasing hormone (GnRH) neurons and increases the secretion of luteinizing hormone (LH), which in turn leads to the increase of androgen production. Moreover, high AMH status in pregnant women with PCOS can lead to masculinization of female offspring and PCOS -like reproductive and neuroendocrine phenotypes in adulthood. At the same time, AMH may also be a new indicator for the diagnosis of PCOS, and the determination of AMH level can also reflect and predict the therapeutic effect of PCOS patients. [ABSTRACT FROM AUTHOR]